公开(公告)号：US11224601B1

公开(公告)日：2022-01-18

申请号：US17029249

申请日：2020-09-23

申请人： AMGEN INC.

发明人： Paul E. Harrington ,  Kate Ashton ,  Sean P. Brown ,  Matthew R. Kaller ,  Todd J. Kohn ,  Brian Alan Lanman ,  Kexue Li ,  Yunxiao Li ,  Jonathan D. Low ,  Ana Elena Minatti ,  Alexander J. Pickrell ,  Markian M. Stec ,  Joshua Taygerly

IPC分类号： A61K31/553 ,  A61P35/02 ,  A61P35/00 ,  C07D498/08

摘要： Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US10821115B2

公开(公告)日：2020-11-03

申请号：US16783269

申请日：2020-02-06

申请人： AMGEN INC.

发明人： Paul E. Harrington ,  Kate Ashton ,  Sean P. Brown ,  Matthew R. Kaller ,  Todd J. Kohn ,  Brian Alan Lanman ,  Kexue Li ,  Yunxiao Li ,  Jonathan D. Low ,  Ana Elena Minatti ,  Alexander J. Pickrell ,  Markian M. Stec ,  Joshua Taygerly

IPC分类号： A61K31/553 ,  A61P35/02 ,  A61P35/00 ,  C07D498/08

摘要： Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US10532042B2

公开(公告)日：2020-01-14

申请号：US15849905

申请日：2017-12-21

申请人： AMGEN INC.

发明人： Brian Alan Lanman ,  Victor J. Cee ,  Alexander J. Pickrell ,  Anthony B. Reed ,  Kevin C. Yang ,  David John Kopecky ,  Hui-Ling Wang ,  Patricia Lopez ,  Kate Ashton ,  Shon Booker ,  Christopher M. Tegley

IPC分类号： C07D487/04 ,  A61K31/428 ,  A61K31/496 ,  A61K31/519 ,  A61P35/00 ,  A61K31/5025 ,  A61K31/502 ,  A61K31/517 ,  C07D401/04 ,  C07D403/04 ,  C07D239/80 ,  C07D417/04 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10 ,  C07D275/04 ,  C07D513/04

摘要： Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

公开(公告)号：US20130079303A1

公开(公告)日：2013-03-28

申请号：US13681230

申请日：2012-11-19

申请人： Amgen Inc.

发明人： Kristin L. ANDREWS ,  Yunxin Y. Bo ,  Shon Booker ,  Victor J. Cee ,  Noel D'Angelo ,  Bradley J. Herberich ,  Fang-Tsao Hong ,  Claire I.M. Jackson ,  Brian Alan Lanman ,  Hongyu Liao ,  Longbin Liu ,  Nobuko Nishimura ,  Mark H. Norman ,  Liping H. Pettus ,  Anthony B. Reed ,  Adrian Leonard Smith ,  Seifu Tadesse ,  Nuria A. Tamayo ,  Bin Wu ,  Ryan Wurz ,  Kevin C. Yang

IPC分类号： C07D473/00 ,  C07D417/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/14

CPC分类号： C07D473/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐; 使用该化合物治疗疾病或病症如癌症的方法; 和含有这些化合物的药物组合物，其中变量如本文所定义。